BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25487918)

  • 1. Preclinical characterization of RSM-932A, a novel anticancer drug targeting the human choline kinase alpha, an enzyme involved in increased lipid metabolism of cancer cells.
    Lacal JC; Campos JM
    Mol Cancer Ther; 2015 Jan; 14(1):31-9. PubMed ID: 25487918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplasmodial activity and mechanism of action of RSM-932A, a promising synergistic inhibitor of Plasmodium falciparum choline kinase.
    Zimmerman T; Moneriz C; Diez A; Bautista JM; Gómez Del Pulgar T; Cebrián A; Lacal JC
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5878-88. PubMed ID: 24041883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new family of choline kinase inhibitors with antiproliferative and antitumor activity derived from natural products.
    Estévez-Braun A; Ravelo AG; Pérez-Sacau E; Lacal JC
    Clin Transl Oncol; 2015 Jan; 17(1):74-84. PubMed ID: 25472447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.
    de la Cueva A; Ramírez de Molina A; Alvarez-Ayerza N; Ramos MA; Cebrián A; Del Pulgar TG; Lacal JC
    PLoS One; 2013; 8(6):e64961. PubMed ID: 23762272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acid ceramidase as a chemotherapeutic target to overcome resistance to the antitumoral effect of choline kinase α inhibition.
    Ramírez de Molina A; de la Cueva A; Machado-Pinilla R; Rodriguez-Fanjul V; Gomez del Pulgar T; Cebrian A; Perona R; Lacal JC
    Curr Cancer Drug Targets; 2012 Jul; 12(6):617-24. PubMed ID: 22515519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug Discovery.
    Zech SG; Kohlmann A; Zhou T; Li F; Squillace RM; Parillon LE; Greenfield MT; Miller DP; Qi J; Thomas RM; Wang Y; Xu Y; Miret JJ; Shakespeare WC; Zhu X; Dalgarno DC
    J Med Chem; 2016 Jan; 59(2):671-86. PubMed ID: 26700752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel 4-amino bis-pyridinium and bis-quinolinium derivatives as choline kinase inhibitors with antiproliferative activity against the human breast cancer SKBR-3 cell line.
    Gómez-Pérez V; McSorley T; See Too WC; Konrad M; Campos JM
    ChemMedChem; 2012 Apr; 7(4):663-9. PubMed ID: 22278967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Near infrared fluorescent imaging of choline kinase alpha expression and inhibition in breast tumors.
    Arlauckas SP; Kumar M; Popov AV; Poptani H; Delikatny EJ
    Oncotarget; 2017 Mar; 8(10):16518-16530. PubMed ID: 28157707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and validation of novel and more effective choline kinase inhibitors against Streptococcus pneumoniae.
    Zimmerman T; Chasten V; Lacal JC; Ibrahim SA
    Sci Rep; 2020 Sep; 10(1):15418. PubMed ID: 32963303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choline kinase inhibitors EB-3D and EB-3P interferes with lipid homeostasis in HepG2 cells.
    Sola-Leyva A; López-Cara LC; Ríos-Marco P; Ríos A; Marco C; Carrasco-Jiménez MP
    Sci Rep; 2019 Mar; 9(1):5109. PubMed ID: 30911014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
    Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
    Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lead optimization-hit expansion of new asymmetrical pyridinium/quinolinium compounds as choline kinase α1 inhibitors.
    Rubbini G; Buades-Martín AB; Kimatrai-Salvador M; Entrena A; Gallo-Mezo MÁ; Ríos-Marco P; Marco C; Mattiuzzo E; Bortolozzi R; Mariotto E; Greco FA; Macchiarulo A; Carrasco-Jiménez MP; Viola G; López-Cara LC
    Future Med Chem; 2018 Aug; 10(15):1769-1786. PubMed ID: 30043647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choline kinase alpha depletion selectively kills tumoral cells.
    Bañez-Coronel M; Ramírez de Molina A; Rodríguez-González A; Sarmentero J; Ramos MA; García-Cabezas MA; García-Oroz L; Lacal JC
    Curr Cancer Drug Targets; 2008 Dec; 8(8):709-19. PubMed ID: 19075594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment.
    Gallego-Ortega D; Ramirez de Molina A; Ramos MA; Valdes-Mora F; Barderas MG; Sarmentero-Estrada J; Lacal JC
    PLoS One; 2009 Nov; 4(11):e7819. PubMed ID: 19915674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (Q)SAR studies to design new human choline kinase inhibitors as antiproliferative drugs.
    Campos JM; Sánchez-Martín RM; Conejo-García A; Entrena A; Gallo MA; Espinosa A
    Curr Med Chem; 2006; 13(11):1231-48. PubMed ID: 16712467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
    Al-Saffar NM; Troy H; Ramírez de Molina A; Jackson LE; Madhu B; Griffiths JR; Leach MO; Workman P; Lacal JC; Judson IR; Chung YL
    Cancer Res; 2006 Jan; 66(1):427-34. PubMed ID: 16397258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choline kinase alpha-Putting the ChoK-hold on tumor metabolism.
    Arlauckas SP; Popov AV; Delikatny EJ
    Prog Lipid Res; 2016 Jul; 63():28-40. PubMed ID: 27073147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery.
    Hernández-Alcoceba R; Fernández F; Lacal JC
    Cancer Res; 1999 Jul; 59(13):3112-8. PubMed ID: 10397253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symmetrical bis-quinolinium compounds: new human choline kinase inhibitors with antiproliferative activity against the HT-29 cell line.
    Sánchez-Martín R; Campos JM; Conejo-García A; Cruz-López O; Báñez-Coronel M; Rodríguez-González A; Gallo MA; Lacal JC; Espinosa A
    J Med Chem; 2005 May; 48(9):3354-63. PubMed ID: 15857141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a Unique Inhibitor-Binding Site on Choline Kinase α.
    Kall SL; Delikatny EJ; Lavie A
    Biochemistry; 2018 Feb; 57(8):1316-1325. PubMed ID: 29389115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.